但这种垄断格局，即将被打破，多款在研新药正从作用机制到给药方式，向Vosoritide发起挑战。Ascendis的TransCon-CNP通过包裹技术延长了药物作用时间，实现了周剂给药，目前正处于FDA审批阶段；而BridgeBio的口服药Infigratinib，则从作用机制到用药体验实现全面突破。
"Families have described to me good experiences, terrible experiences. It is patchy, it is inconsistent and what this investigation is about, is trying to find out the things that move us from poor and bad to good and excellent.
，这一点在heLLoword翻译官方下载中也有详细论述
第四十五条 仲裁员存在可能导致当事人对其独立性、公正性产生合理怀疑情形的，该仲裁员应当及时向仲裁机构书面披露。，详情可参考谷歌浏览器【最新下载地址】
Even this relatively clean version requires: a TransformStream, manual TextEncoder and TextDecoder, and explicit lock release.